Products Loncastuximab tesirine
Loncastuximab tesirine Phase 2 Completed ⚡ Active Diffuse Large B-Cell Lymphoma Refractory
Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
Aug 1, 2018 → Aug 9, 2022
About Loncastuximab tesirine Loncastuximab tesirine is a phase 2 stage product being developed by ADC Therapeutics for Diffuse Large B-Cell Lymphoma Refractory. The current trial status is completed. This product is registered under clinical trial identifier NCT03589469. Target conditions include Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent.
Clinical Trials (3) NCT ID Phase Status Start Completion Indication NCT04705454 Pre-clinical Completed — — Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) NCT05660395 Phase 1 Recruiting Aug 28, 2023 Apr 5, 2027 Diffuse Large B-Cell Lymphoma NCT03589469 Phase 2 Completed Aug 1, 2018 Aug 9, 2022 Diffuse Large B-Cell Lymphoma Refractory
Competing Products 20 competing products in Diffuse Large B-Cell Lymphoma Refractory
See all competitors Product Company Stage Hype Score IVA337 + Placebo Inventiva Phase 2 Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) Eli Lilly Phase 2 rituximab Celltrion Phase 1 YM155 Astellas Pharma Phase 2 enzastaurin + gemcitabine + rituximab + oxaliplatin Eli Lilly Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Johnson & Johnson Phase 2 VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Johnson & Johnson Phase 2 Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine AbbVie Phase 3 ABBV-525 AbbVie Phase 1 rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + Epcoritamab AbbVie Phase 1/2 Copanlisib + Venetoclax AbbVie Phase 1/2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 Epcoritamab + Lenalidomide AbbVie Phase 2 Venetoclax + Selinexor AbbVie Phase 1 Epcoritamab AbbVie Phase 1 Loncastuximab Tesirine and Epcoritamab AbbVie Phase 2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 bendamustine + navitoclax + rituximab AbbVie Phase 2 Epcoritamab AbbVie Phase 2 Epcoritamab (monotherapy) + Epcoritamab + Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + Gemcitabine and oxaliplatin + Epcoritamab (maintenance) + Rituximab and lenalidomide AbbVie Phase 1/2
Other Products from ADC Therapeutics